Latest News
Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market
FREEHOLD, N.J., March 27, 2025 /PRNewswire/ -- Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more...
Armas Pharmaceuticals and Steriscience Enter Strategic Partnership to Commercialize Products for the U.S. Market
Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intends to launch up to eight products through Armas...
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part of Armas' consistently growing product line, bringing their portfolio count...
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Armas Pharmaceuticals Inc. (Armas) is announcing the launch of generic Tarceva® (a trademark of Genentech USA, Inc) Tablets. Erlotinib is now available in 25mg, 100mg and 150mg strengths. This is Armas' third oral solid to be added to their oncology portfolio. "I am...
Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market
Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced today, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in...